Skip to content

Study · Randomized controlled trial · n = 238 · 2023

4 results

Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.

Zhao Y, Zhang H, Zhao Z, Liu F, Dong M, Chen L, Shen M, Luan Z, Zhang H, Wu J, Li C, Chen J and 8 more

Show all authors

Li C, Liu Z, Chen Y, Zheng A, Li H, Wang S, Jin W, Sun G

Journal of medical virology1 Aug 2023Cited by 7 (Europe PMC)

PMID37605995 (opens in a new tab)DOI10.1002/jmv.29035 (opens in a new tab)PepBankPUB-37605995
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In 238 adult inpatients with Omicron BA.5.1.3 COVID-19, no severe adverse events were observed with oral LL‑37 during hospitalization and follow-up.

    In plain wordsIn hospitalized adults with COVID-19, no severe side effects were seen with oral LL‑37 during the hospital stay and follow-up.

    Peptide
    LL-37
    Outcome
    Not applicableSevere adverse events during hospitalization and follow-up
    Study

    n = 238

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral (recombinant LL-37 expressed in Lactococcus lactis)As given in this study (human).

    Source sentences

    Summary
    No severe AEs were observed during hospitalization and follow-up investigation.
    1 context sentence
    Summary · context
    A total of 238 adult inpatients, open-labelled, randomized, placebo-controlled, single-center study was conducted to investigate the primary end points, including negative conversion time (NCT) of SARS-CoV-2 RNA and adverse events (AEs).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adult inpatients with Omicron BA.5.1.3 COVID-19 treated within 6 days of case confirmation, oral LL‑37 shortened the negative conversion time of SARS-CoV-2 RNA versus placebo (9.80 vs 14.04, p < 0.01).

    In plain wordsIn adults hospitalized with Omicron COVID-19, oral LL‑37 given early shortened the time to a negative virus test versus placebo.

    Peptide
    LL-37
    Outcome
    DecreaseNegative conversion time (NCT) of SARS-CoV-2 RNA when treated early
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · oral (recombinant LL-37 expressed in Lactococcus lactis)As given in this study (human).

    Measurements

    Negative conversion time (NCT) of SARS-CoV-2 RNA
    9.8
    Oral LL-37, treated early (6th day of case confirmation); SD 2.67; unit not stated in abstract
    Negative conversion time (NCT) of SARS-CoV-2 RNA
    14.04
    Placebo; SD 5.89; unit not stated in abstract

    Source sentences

    Summary
    As early as intervened on 6th day of case confirmed, Oral LL-37 could significantly shorten NCT (LL-37 9.80 ± 2.67 vs. placebo 14.04 ± 5.89, p < 0.01).
    1 context sentence
    Summary · context
    A total of 238 adult inpatients, open-labelled, randomized, placebo-controlled, single-center study was conducted to investigate the primary end points, including negative conversion time (NCT) of SARS-CoV-2 RNA and adverse events (AEs).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adult inpatients with Omicron BA.5.1.3 COVID-19, oral LL‑37 treatment within 6 days had an adjusted hazard ratio of 2.427 (95% CI 1.239-4.751) for a negative SARS-CoV-2 RNA result versus placebo.

    In plain wordsIn adults hospitalized with COVID-19, oral LL‑37 started within 6 days was linked to a faster return to a negative virus test than placebo.

    Peptide
    LL-37
    Outcome
    IncreaseNucleic acid negative outcome (adjusted HR), Oral LL-37 within 6 days versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · oral (recombinant LL-37 expressed in Lactococcus lactis)As given in this study (human).

    Measurements

    Adjusted hazard ratio, nucleic acid negative outcome
    2.427 HR
    Oral LL-37 within 6 days versus placebo; 95% CI 1.239-4.751; p = 0.0097

    Source sentences

    Summary
    the adjusted HR of Oral LL-37 within 6 days is higher than placebo (HR: 2.427 95% CI: 1.239-4.751, p = 0.0097).
    1 context sentence
    Summary · context
    A total of 238 adult inpatients, open-labelled, randomized, placebo-controlled, single-center study was conducted to investigate the primary end points, including negative conversion time (NCT) of SARS-CoV-2 RNA and adverse events (AEs).
  4. 04HumanObservational studyEfficacy outcome

    In adult inpatients with Omicron BA.5.1.3 COVID-19 given oral LL‑37, treatment within 6 days had an adjusted hazard ratio of 6.276 (95% CI 3.631-10.848) for a negative SARS-CoV-2 RNA result versus later treatment.

    In plain wordsIn adults hospitalized with COVID-19, giving oral LL‑37 earlier was linked to a faster return to a negative virus test than giving it later.

    Peptide
    LL-37
    Outcome
    IncreaseNucleic acid negative outcome (adjusted HR), Oral LL-37 treated within 6 days versus 7-day-later
    Study

    n: not reported in source

    Comparator
    Oral LL-37 treated later (7-day-later)
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · oral (recombinant LL-37 expressed in Lactococcus lactis)As given in this study (human).

    Measurements

    Adjusted hazard ratio, nucleic acid negative outcome
    6.276 HR
    Oral LL-37 treated within 6 days versus 7-day-later; 95% CI 3.631-10.848; p < 0.0001

    Source sentences

    Summary
    For Oral LL-37, as early as treated in 6 days, the adjusted hazard ratio (HR) for a primary event of nucleic acid negative outcome was 6.27-fold higher than 7-day-later (HR: 6.276, 95% confidence interval [CI]: 3.631-10.848, p < 0.0001)
    1 context sentence
    Summary · context
    A total of 238 adult inpatients, open-labelled, randomized, placebo-controlled, single-center study was conducted to investigate the primary end points, including negative conversion time (NCT) of SARS-CoV-2 RNA and adverse events (AEs).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.